Last reviewed · How we verify

Neuroleptanalgesic treatment

GCS Ramsay Santé pour l'Enseignement et la Recherche · Phase 1 active Small molecule

Neuroleptanalgesic treatment is a Small molecule drug developed by GCS Ramsay Santé pour l'Enseignement et la Recherche. It is currently in Phase 1 development. Also known as: Hypnovel.

At a glance

Generic nameNeuroleptanalgesic treatment
Also known asHypnovel
SponsorGCS Ramsay Santé pour l'Enseignement et la Recherche
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Neuroleptanalgesic treatment

What is Neuroleptanalgesic treatment?

Neuroleptanalgesic treatment is a Small molecule drug developed by GCS Ramsay Santé pour l'Enseignement et la Recherche.

Who makes Neuroleptanalgesic treatment?

Neuroleptanalgesic treatment is developed by GCS Ramsay Santé pour l'Enseignement et la Recherche (see full GCS Ramsay Santé pour l'Enseignement et la Recherche pipeline at /company/gcs-ramsay-sant-pour-l-enseignement-et-la-recherche).

Is Neuroleptanalgesic treatment also known as anything else?

Neuroleptanalgesic treatment is also known as Hypnovel.

What development phase is Neuroleptanalgesic treatment in?

Neuroleptanalgesic treatment is in Phase 1.

Related